SAN DIEGO, Feb. 6 /PRNewswire-FirstCall/ -- dj Orthopedics, Inc., (NYSE: DJO), today announced that it plans to publicly offer 6,000,000 shares of its common stock. It expects that the offering will consist of 2,750,000 shares to be offered by dj Orthopedics and 3,250,000 shares to be offered by certain of its stockholders. The offering will be made pursuant to the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission. dj Orthopedics further expects that the Company and one of the selling stockholders will grant an over allotment option to the underwriters for the offering of up to 900,000 shares. J.P. Morgan Securities Inc. and Lehman Brothers Inc. will act as joint book-running managers for the proposed offering. Co-managers of the offering are Piper Jaffray & Co., Wachovia Capital Markets, LLC, First Albany Capital Inc. and WR Hambrecht + Co, LLC.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A shelf registration statement relating to the shares that the Company intends to sell has previously been filed with, and declared effective by, the Securities and Exchange Commission. A copy of the prospectus supplement and the prospectus related to the offering can be obtained when available from J.P. Morgan Securities Inc., One Chase Manhattan Plaza, Floor 5B, New York, New York 10081 and from Lehman Brothers Inc., c/o ADP Financial Services Prospectus Fulfillment, 1155 Long Island Avenue, Edgewood, New York 11717.
About dj Orthopedics, Inc.
dj Orthopedics is a global medical device company specializing in rehabilitation and regeneration products for the non-operative orthopedic and spine markets. The Company's broad range of over 600 rehabilitation products, including rigid knee braces, soft goods and pain management products, are used to prevent injury, to treat chronic conditions and to aid in recovery after surgery or injury. The Company's regeneration products consist of bone growth stimulation devices that are used to treat nonunion fractures and as an adjunct therapy after spinal fusion surgery.
The Company sells its products in the United States and in more than 30 other countries through networks of agents, distributors and its direct sales force that market its products to orthopedic and spine surgeons, podiatrists, orthopedic and prosthetic centers, third-party distributors, hospitals, surgery centers, physical therapists, athletic trainers and other healthcare professionals.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements relate to, among other things, the Company's financing plans. These forward-looking statements are based on the Company's current expectations and are subject to a number of risks, uncertainties and assumptions, such as stock market price fluctuations and those risks detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no bligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE dj Orthopedics, Inc.
-0- 02/06/2004
CO: dj Orthopedics, Inc.
ST: California
IN: HEA MTC BIO
SU: OFR
BM-AP
-- LAF056 --
8384 02/06/2004 16:18 EST http://www.prnewswire.com
Company Investor/Media Contact:
DJO Incorporated
Mark Francois
Director of Corporate Communications & Investor Relations
760-734-4766
